Challenges in Implementing Futility Schemes, with Reference to Aducanumab
- 3 February 2023
- journal article
- review article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 57 (3) , 515-520
Abstract
Stopping an ongoing clinical trial based on an interim analysis that shows poor outcomes, often referred to as a judgment of “futility”, is a familiar feature in current clinical trials practice. Interim data can be misleading, and the implications of prematurely terminating a trial that should not stop are severe. It is thus critical that designs allowing futility stopping be planned and implemented carefully and cautiously. A recent Phase III development program for aducanumab in Alzheimer’s disease was halted based on a pre-defined futility guideline, yet based upon updated data and closer examination, the terminated studies became the basis for a regulatory submission. Not surprisingly, this situation generated much controversy and discussion. It provides a good basis for illustrating important principles governing the planning and implementation of futility schemes.Keywords
This publication has 6 references indexed in Scilit:
- Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's DiseaseThe Journal Of Prevention of Alzheimer's Disease, 2022
- Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019Alzheimer's & Dementia, 2020
- Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky BusinessThe Journal Of Prevention of Alzheimer's Disease, 2020
- Superiority of combining two independent trials in interim futility analysisStatistical Methods in Medical Research, 2019
- On the Use of Co-Data in Clinical TrialsStatistics in Biopharmaceutical Research, 2016
- Alternative Views On Setting Clinical Trial Futility CriteriaJournal of Biopharmaceutical Statistics, 2014